Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
J Nutr Sci ; 9: e59, 2020.
Article in English | MEDLINE | ID: mdl-33489104

ABSTRACT

Eriocitrin is a citrus flavonoid with a high capacity to reduce the oxidative stress related to metabolic disorders and obesity. We assessed the effects of low doses of eriocitrin on the oxidative stress, inflammation, and metabolism of glucose and lipids of high-fat diet (HFD)-fed obese mice. Fifty male C57BL/6J mice were randomly assigned into five groups (n 10). The mice were fed an HFD (45 % kcal from fat, i.e. lard) for 4 weeks for obesity induction. After this period, the mice continued receiving the same HFD, but supplemented with eriocitrin at 10, 25 or 100 mg/kg body weight (bw) for an additional 4 weeks. Control groups were fed with standard diet (10 % kcal of fat, i.e. soy oil) or with HFD without eriocitrin, for eight consecutive weeks. At the end of the study, mice supplemented with eriocitrin showed lower levels of blood serum glucose and blood and liver triacylglycerols (P < 0⋅05). There was also improved levels of insulin, HOMA-IR, total-cholesterol, resistin and lipid peroxidation in the supplemented mice. It was concluded that the 25 mg dose of eriocitrin improved all the parameters studied and had positive effects on oxidative stress, systemic inflammation and metabolism of lipids and glucose in general.


Subject(s)
Diet, High-Fat , Flavanones/administration & dosage , Obesity/metabolism , Animals , Blood Glucose/metabolism , Lipids , Male , Mice , Mice, Inbred C57BL , Random Allocation
2.
J Dent Res ; 94(12): 1691-7, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26220958

ABSTRACT

Bone formation is dependent on the differentiation of osteoblasts from mesenchymal stem cells (MSCs). In addition to serving as progenitors, MSCs reduce inflammation and produce factors that stimulate tissue formation. Upon injury, MSCs migrate to the periodontium, where they contribute to regeneration. We examined the effect of clopidogrel and aspirin on MSCs following induction of periodontitis in rats by placement of ligatures. We showed that after the removal of ligatures, which induces resolution of periodontal inflammation, clopidogrel had a significant effect on reducing the inflammatory infiltrate. It also increased the number of osteoblasts and MSCs. Mechanistically, the latter was linked to increased proliferation of MSCs in vivo and in vitro. When given prior to inducing periodontitis, clopidogrel had little effect on MSC or osteoblasts numbers. Applying aspirin before or after induction of periodontitis did not have a significant effect on the parameters measured. These results suggest that clopidogrel may have a positive effect on MSCs in conditions where a reparative process has been initiated.


Subject(s)
Cell Proliferation/drug effects , Mesenchymal Stem Cells/drug effects , Periodontitis/physiopathology , Purinergic P2Y Receptor Antagonists/pharmacology , Ticlopidine/analogs & derivatives , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Aspirin/pharmacology , Cell Movement/physiology , Clopidogrel , Gingiva/cytology , Gingiva/pathology , Male , Mesenchymal Stem Cells/physiology , Osteoblasts/drug effects , Osteoblasts/physiology , Periodontitis/pathology , Rats , Rats, Sprague-Dawley , Ticlopidine/pharmacology
3.
Horm Metab Res ; 46(3): 193-200, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24526374

ABSTRACT

This study evaluated the alveolar bone response to testosterone and the impact of Resolvin D2 (RvD2) on testosterone-induced osteoblast function. For the in vivo characterization, 60 male adult rats were used. Treatments established sub-physiologic (L), normal (N), or supra-physiologic (H) concentrations of testosterone. Forty rats were subjected to orchiectomy; 20 rats received periodical testosterone injections while 20 rats received testicular sham-operation. Four weeks after the surgeries, 10 rats in each group received a subgingival ligature around the lower first molars to induce experimental periodontal inflammation and bone loss. In parallel, osteoblasts were differentiated from neonatal mice calvariae and treated with various doses of testosterone for 48 h. Cell lysates and conditioned media were used for the determination of alkaline phosphatase, osteocalcin, RANKL, and osteoprotegerin. Micro-computed tomography linear analysis demonstrated that bone loss was significantly increased for both L and H groups compared to animals with normal levels of testosterone. Gingival IL-1ß expression was increased in the L group (p<0.05). Ten nM testosterone significantly decreased osteocalcin, RANKL, and OPG levels in osteoblasts; 100 nM significantly increased the RANKL:OPG ratio. RvD2 partially reversed the impact of 10 nM testosterone on osteocalcin, RANKL, and OPG. These findings suggest that both L and H testosterone levels increase inflammatory bone loss in male rats. While low testosterone predominantly increases the inflammatory response, high testosterone promotes a higher osteoblast-derived RANKL:OPG ratio. The proresolving mediator RvD2 ameliorates testosterone-derived downregulation of osteocalcin, RANKL, and OPG in primary murine osteoblasts suggesting a direct role of inflammation in osteoblast function.


Subject(s)
Bone and Bones/metabolism , Bone and Bones/pathology , Inflammation/metabolism , Inflammation/pathology , Testosterone/pharmacology , Alkaline Phosphatase/metabolism , Animals , Bone and Bones/diagnostic imaging , Bone and Bones/drug effects , Cells, Cultured , Cytokines/metabolism , Docosahexaenoic Acids/pharmacology , Down-Regulation/drug effects , Inflammation/blood , Male , Mice , Osteoblasts/drug effects , Osteoblasts/metabolism , Osteoblasts/pathology , Osteocalcin/metabolism , Osteoprotegerin/metabolism , Periodontal Diseases/blood , RANK Ligand/metabolism , Rats , Testosterone/blood , X-Ray Microtomography
4.
J Periodontal Res ; 49(6): 729-35, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24372313

ABSTRACT

BACKGROUND AND OBJECTIVE: After activation, platelets express mediators that modulate inflammation. We hypothesized that drug-induced platelet inactivation may interfere in the inflammatory process in experimental periodontal disease by suppressing the release of biological mediators to the injury site. MATERIAL AND METHODS: To evaluate the effects of antiplatelet drugs on experimental periodontal disease, 60 rats were randomly assigned to six groups (n = 10) and ligatures were placed around lower first molars in three groups. The other three groups were not subjected to the induction of periodontal disease and were used as negative controls. During the experimental period, animals were given aspirin (30 mg/kg) or clopidogrel (75 mg/kg) intragastrically once daily for 3 d. On day 3, they were killed and gingival tissue were used to evaluate myeloperoxidase activity and the expression of the chemokine CXCL4. Hemi-mandibles were used for microscopic evaluation. RESULTS: Clopidogrel significantly reduced the inflammatory infiltrate and increased the amount of collagen fibers. Histometric analysis showed that clopidogrel impaired alveolar bone loss. Expression of CXCL4 was significantly increased (p < 0.001) in rats subjected to periodontal disease. Systemic administration of aspirin and clopidogrel induced a significant decrease ( p < 0.05) in the expression of CXCL4. Treatment with antiplatelet drugs resulted in a significant reduction of myeloperoxidase activity when compared to saline-treated animals with periodontal disease. CONCLUSION: Clopidogrel but not aspirin showed the ability of preventing bone loss in experimental periodontitis.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Periodontitis/drug therapy , Platelet Aggregation Inhibitors/therapeutic use , Alveolar Bone Loss/prevention & control , Animals , Aspirin/therapeutic use , Clopidogrel , Collagen/drug effects , Connective Tissue/drug effects , Connective Tissue/pathology , Disease Models, Animal , Gingiva/drug effects , Gingiva/pathology , Inflammation Mediators/antagonists & inhibitors , Male , Mandibular Diseases/prevention & control , Periodontitis/immunology , Periodontitis/pathology , Peroxidase/analysis , Platelet Factor 4/analysis , Random Allocation , Rats , Rats, Sprague-Dawley , Ticlopidine/analogs & derivatives , Ticlopidine/therapeutic use
5.
Transplant Proc ; 45(2): 778-82, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23267796

ABSTRACT

The administration of cyclosporine A (CsA) has been associated with significant bone loss and increased bone remodeling. The present investigation was designed to evaluate the effects of CsA on alveolar bone of rats subjected to experimental periodontitis, using histomorphometric and histological analysis. Twenty-four rats were divided into groups with 6 animals each: 1, control; 2, rats with ligature around the lower first molars; 3, rats with ligature around the lower first molars and that were treated with 10 mg CsA/kg of body weight/d; and 4, rats treated with 10 mg CsA/kg of body weight/d. At the end of 30 days, rats were humanely killed and subjected to a histological processing, with analysis of the distance cemento-enamel junction and alveolar bone crest, bone area, eroded bone area, and cemento surface. All of them were assessed at the mesial region of the alveolar bone. The CsA therapy combined with ligature placement decreased bone area and increased the eroded bone area around the tooth surface. The results at the histological analysis showed the same combination and changes. Therefore, in spite of the lack of a direct effect on the alveolar bone height, the CsA therapy intensified the imbalance of the alveolar bone homeostasia in a rat model of experimental periodontitis.


Subject(s)
Alveolar Bone Loss/chemically induced , Alveolar Process/drug effects , Bone Remodeling/drug effects , Cyclosporine/toxicity , Immunosuppressive Agents/toxicity , Periodontitis/complications , Alveolar Bone Loss/pathology , Alveolar Process/pathology , Animals , Disease Models, Animal , Ligation , Male , Molar/surgery , Periodontitis/pathology , Rats , Rats, Sprague-Dawley , Time Factors
6.
Int J Dent Hyg ; 9(4): 279-83, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21356033

ABSTRACT

OBJECTIVE: The aim of this study was to investigate the effectiveness of two alternatives methods for the disinfection of oral cleaning devices. METHODS: One type of toothbrush and two types of tongue scrapers (steel and plastic) were tested in this study. Sixteen specimens of each group were cut with standardized dimensions, contaminated separately with Candida albicans, Streptococcus mutans and Staphylococcus aureus and incubated for 24 h. After this, oral cleaning devices were washed in saline solution to remove non-adhered cells and divided into two groups (n = 8), one irradiated in microwave and other immersed in 3.78% sodium perborate solution, and evaluated for microbial recovery. The values of cfu of each group of microorganism after disinfection were compared by Kruskal-Wallis and Dunn non-parametric test, considering 95% of confidence. RESULTS: The toothbrush harboured a significant larger number of viable organisms than the tongue scrapers. The steel tongue scraper was less susceptible to adhesion of the three oral microorganisms. The time required to inactivate all contaminating microorganisms using microwave oven was 1 min and, for the immersion in 3.78% sodium perborate solution, was 2 and 3 h, respectively, for C. albicans and S. mutans/S. aureus. CONCLUSION: Microwave irradiation proved to be an effective alternative method to the disinfection of tongue cleaners and toothbrushes.


Subject(s)
Dental Devices, Home Care/microbiology , Dental Disinfectants/pharmacology , Disinfection/methods , Microwaves , Toothbrushing/instrumentation , Biofilms/drug effects , Biofilms/radiation effects , Borates/pharmacology , Candida albicans/drug effects , Candida albicans/radiation effects , Colony Count, Microbial , Equipment Design , Microbial Viability/drug effects , Microbial Viability/radiation effects , Plastics , Stainless Steel , Staphylococcus aureus/drug effects , Staphylococcus aureus/radiation effects , Streptococcus mutans/drug effects , Streptococcus mutans/radiation effects , Tongue , Tooth Bleaching Agents/pharmacology
7.
J Periodontal Res ; 46(2): 269-79, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21306385

ABSTRACT

BACKGROUND AND OBJECTIVE: Curcumin is a plant-derived dietary spice with various biological activities, including anticarcinogenic and anti-inflammatory effects. Its therapeutic applications have been studied in a variety of conditions, including rheumatoid arthritis, colon cancer and depression, but no studies have evaluated the effects of curcumin on periodontal disease in vivo. MATERIAL AND METHODS: Experimental periodontal disease was induced in rats by placing cotton ligatures around both lower first molars. Curcumin was given to the rats by the intragastric route daily at two dosages (30 and 100 mg/kg) for 15 d. Control animals received ligatures but only the corn oil vehicle by gavage, and no treatment-negative control animals were included. Bone resorption was assessed by micro-computed tomography, and the inflammatory status was evaluated by stereometric analysis. Both RT-qPCR and ELISA were used to determine the expression of interleukin-6, tumor necrosis factor-α and prostaglandin E(2) synthase in the gingival tissues. Modulation of p38 MAPK and nuclear factor-κB activation were assessed by western blotting. RESULTS: Bone resorption was effectively induced in the experimental period, but it was not affected by either dose of curcumin. Curcumin effectively inhibited cytokine gene expression at both the mRNA and the protein level and produced a dose-dependent inhibition of the activation of nuclear factor-κB in the gingival tissues. Activation of p38 MAPK was not inhibited by curcumin. Curcumin-treated animals also presented a marked reduction of the inflammatory cell infiltrate and increased collagen content and fibroblastic cell numbers. CONCLUSION: Curcumin did not prevent alveolar bone resorption, but its potent anti-inflammatory effect suggests that it may have a therapeutic potential in periodontal diseases.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Curcumin/therapeutic use , Periodontitis/prevention & control , Alveolar Bone Loss/prevention & control , Alveolar Process/drug effects , Alveolar Process/pathology , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Cell Count , Collagen/drug effects , Curcumin/administration & dosage , Cyclooxygenase 2/analysis , Dose-Response Relationship, Drug , Fibroblasts/drug effects , Gingiva/drug effects , Gingiva/pathology , Image Processing, Computer-Assisted/methods , Imaging, Three-Dimensional/methods , Inflammation , Interleukin-6/analysis , Intramolecular Oxidoreductases/analysis , Male , NF-kappa B/analysis , NF-kappa B/drug effects , Prostaglandin-E Synthases , Random Allocation , Rats , Rats, Sprague-Dawley , Tumor Necrosis Factor-alpha/analysis , Tumor Necrosis Factor-alpha/drug effects , X-Ray Microtomography/methods , p38 Mitogen-Activated Protein Kinases/analysis , p38 Mitogen-Activated Protein Kinases/drug effects
8.
Rev. bras. plantas med ; 13(4): 492-499, 2011. tab
Article in Portuguese | LILACS | ID: lil-611454

ABSTRACT

O interesse por medicamentos alternativos, principalmente daqueles provenientes de extratos naturais, tem aumentado nas últimas décadas. A Melaleuca alternifolia é um arbusto pertencente ao gênero Melaleuca, popularmente conhecida como "árvore de chá", cujo principal produto é o óleo essencial (TTO - tea tree oil), de grande importância medicinal por possuir comprovada ação bactericida e antifúngica contra diversos patógenos humanos. Em virtude da atividade terapêutica em diversas especialidades médicas, o TTO passou a ser empregado na área odontológica. Esta revisão de literatura foi realizada com o objetivo de discutir os ensaios já realizados com o TTO contra microrganismos relacionados à doença cárie, doença periodontal e problemas pulpares. O óleo de Melaleuca tem demonstrado boa ação antibacteriana in vitro contra microrganismos bucais, porém, pesquisas envolvendo o estudo do mecanismo de ação sobre as células microbianas ou estudos in vivo ainda são escassos e precisam ser realizados, já que esse produto pode ser útil na odontologia, seja na manutenção química da higiene ou prevenção de doenças bucais.


The interest in alternative medicines, especially those from natural extracts, has increased in recent decades. Melaleuca alternifolia is a shrub belonging to the genus Melaleuca, popularly known as "tea tree", the main product of which is its essential oil (TTO - tea tree oil), of great medicinal importance for its proven bactericidal and antifungal activity against several human pathogens. By virtue of its therapeutic activity in various medical specialties, TTO is now used in dentistry. This literature review was conducted in order to discuss the tests already carried out with TTO against microorganisms related to dental caries, periodontal disease and pulpal problems. Melaleuca oil has shown good in vitro antibacterial activity against oral microorganisms; however, research involving the study of its mechanism of action on the microbial cells or in vivo studies are still scarce and need to be done since this product may be useful in dentistry, either in the chemical maintenance of hygiene or in the prevention of oral diseases.


Subject(s)
Antifungal Agents , Dental Research , Mouth Diseases/immunology , Mouth Diseases/microbiology , Tea Tree Oil/administration & dosage , Plant Extracts/pharmacology
9.
J Periodontal Res ; 45(2): 184-92, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19778332

ABSTRACT

BACKGROUND AND OBJECTIVE: Platelets contain factors, including VEGF and endostatin, that can modulate the healing process. We evaluated the effects of severe thrombocytopenia on periodontal healing in rats and determined the contribution of VEGF and endostatin to the healing process. MATERIAL AND METHODS: Rats were distributed into three test groups and two control groups. Cotton ligatures were placed at the gingival margin level of the lower first molar in the test groups. Sham-operated rats and rats in one of the periodontitis groups were killed 15 days later. Rats in the remaining two periodontitis groups had the ligatures removed in order to study the spontaneous recovery from the periodontal disease 15 days later, and these rats were treated with rabbit antiplatelet serum, in order to induce thrombocytopenia, or normal rabbit serum. An additional group without ligatures received antiplatet serum in the same period. RESULTS: After ligature removal, rats treated with normal rabbit serum showed reduced myeloperoxidase activity, decreased alveolar bone loss and increased numbers of blood vessels. Thrombocytopenia caused a delay in alveolar bone regeneration, a decrease in the number of vessels and a modest decrease in myeloperoxidase activity. In the rats with periodontitis, serum endostatin concentrations were slightly decreased and serum VEGF remained unchanged compared with sham-operated animals. After ligature removal, a significant VEGF increase and endostatin decrease were observed in the rats treated with normal rabbit serum. Thrombocytopenia led to a dramatic fall in both VEGF and endostatin concentrations. CONCLUSION: Thrombocytopenia leads to a delay of periodontal healing in the situation of experimental periodontitis, which might be mediated in part by a decrease in the serum concentration of VEGF and endostatin derived from the platelets. However, other factors derived from the platelets may also have contributed to a delay of periodontal healing in the rats with thrombocytopenia.


Subject(s)
Angiogenesis Inhibitors/physiology , Angiogenic Proteins/physiology , Endostatins/physiology , Periodontitis/physiopathology , Thrombocytopenia/physiopathology , Vascular Endothelial Growth Factor A/physiology , Alveolar Bone Loss/pathology , Alveolar Bone Loss/physiopathology , Angiogenesis Inhibitors/blood , Angiogenic Proteins/blood , Animals , Blood Platelets/immunology , Blood Platelets/physiology , Bone Regeneration/physiology , Bone Remodeling/physiology , Endostatins/blood , Immune Sera , Male , Neovascularization, Physiologic/physiology , Periodontitis/blood , Periodontitis/pathology , Peroxidase/analysis , Platelet Count , Rabbits , Rats , Rats, Sprague-Dawley , Thrombocytopenia/blood , Time Factors , Vascular Endothelial Growth Factor A/blood , Wound Healing/physiology
10.
Oral Microbiol Immunol ; 24(6): 437-50, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19832795

ABSTRACT

INTRODUCTION: The aim of this study was to investigate the oral colonization profile of Candida albicans strains isolated from diabetic patients and their non-diabetic consorts. In addition hydrolytic enzyme activity of these isolates was analysed. METHODS: The genetic diversity of C. albicans oral isolates from 52 couples was established using isoenzyme marker and cluster analysis. Hydrolytic enzyme characteristics, namely secreted aspartyl proteinases (SAPs) and phospholipases (PLs) were also analysed. RESULTS: Simultaneous colonization by C. albicans was observed in the consorts of 12 couples (23.1%). Patterns of monoclonal and polyclonal oral colonization by C. albicans strains were identified and the coexistence of identical or highly related strains was observed in both members of eight couples. The genetic diversity observed in the total yeast population revealed four large, genetically distinct groups (A to D) and the coexistence of strains in couples or consorts conjugally unrelated. SAP and PL activity was observed in the majority of C. albicans isolates without any association to particular strain, strain clusters (highly related isolates), or clinical characteristics of the consorts (diabetic, non-diabetic, and gender). CONCLUSION: Possible sources of transmission and oral propagation of groups (clusters) of strains of C. albicans can occur between diabetic and non-diabetic consorts. A conjugal genotypic identity exists in most C. albicans-positive couples, that is, both consorts share identical or highly related strains; however, this identity is not couple-specific as seen by the coexistence of clusters in couples and unrelated consorts.


Subject(s)
Aspartic Acid Proteases/metabolism , Candida albicans/enzymology , Candida albicans/genetics , Candidiasis, Oral/microbiology , Diabetes Complications , Phospholipases/metabolism , Adult , Aged , Alleles , Candidiasis, Oral/complications , Candidiasis, Oral/transmission , Cluster Analysis , Disease Transmission, Infectious , Electrophoresis/methods , Female , Genetic Variation , Humans , Male , Middle Aged , Species Specificity , Spouses , Virulence
11.
Transplant Proc ; 41(5): 1871-4, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19545747

ABSTRACT

Cyclosporine (CsA) and tacrolimus (FK 506) exert complex, incompletely understood actions on bone. The objective of the study was to evaluate the effects of long-term tacrolimus therapy on the periodontium. Rats were treated for 60, 120, 180, and 240 days with daily subcutaneous injections of 1 mg/kg body weight of FK 506. After the experimental period, we obtained serum levels of calcium and alkaline phosphatase (ALP). After histological processing, the alveolar bone and cementum, as well as volume densities of bone (V(b)) and osteoclasts (V(o)), were assessed at the regions of the lower first molar. There was a tendency toward a statistically significant decrease in ALP levels with FK 506; however, serum calcium levels increased during the long periods. At 60, 180, and 240 days of treatment with FK 506, we did not observe V(b) and V(o) alterations. At 120 days of treatment, there was an evident decrease in V(b), but it did not show alveolar bone loss. We did not observe any alterations of cementum among rats treated with FK 506. It may be concluded that FK 506 administration did not induce side effects on the periodontium.


Subject(s)
Bone Cements/therapeutic use , Bone Density/drug effects , Bone and Bones/pathology , Immunosuppressive Agents/therapeutic use , Tacrolimus/therapeutic use , Animals , Bone and Bones/drug effects , Cyclosporine/therapeutic use , Male , Mandible/drug effects , Mandible/physiology , Rats
12.
J Periodontal Res ; 44(4): 479-88, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19076990

ABSTRACT

BACKGROUND AND OBJECTIVE: Cyclosporine A treatment is important in the therapy of a number of medical conditions; however, alveolar bone loss is an important negative side-effect of this drug. As such, we evaluated whether concomitant administration of simvastatin would minimize cyclosporine A-associated alveolar bone loss in rats subjected, or not, to experimental periodontal disease. MATERIAL AND METHODS: Groups of 10 rats each were treated with cyclosporine A (10 mg/kg/day), simvastatin (20 mg/kg/day), cyclosporine A and simvastatin concurrently (cyclosporine A/simvastatin) or vehicle for 30 days. Four other groups of 10 rats each received a cotton ligature around the lower first molar and were treated similarly with cyclosporine A, simvastatin, cyclosporine A/simvastatin or vehicle. Calcium (Ca(2+)), phosphorus and alkaline phosphatase levels were evaluated in serum. Expression levels of interleukin-1beta, prostaglandin E(2) and inducible nitric oxide synthase were evaluated in the gingivomucosal tissues. Bone volume and numbers of osteoblasts and osteoclasts were also analyzed. RESULTS: Treatment with cyclosporine A in rats, with or without ligature, was associated with bone loss, represented by a lower bone volume and an increase in the number of osteoclasts. Treatment with cyclosporine A was associated with bone resorption, whereas simvastatin treatment improved cyclosporine A-associated alveolar bone loss in all parameters studied. In addition, simvastatin, in the presence of inflammation, can act as an anti-inflammatory agent. CONCLUSION: This study shows that simvastatin therapy leads to a reversal of the cyclosporine A-induced bone loss, which may be mediated by downregulation of interleukin-1beta and prostaglandin E(2) production.


Subject(s)
Alveolar Bone Loss/chemically induced , Cyclosporine/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Immunosuppressive Agents/adverse effects , Simvastatin/pharmacology , Alkaline Phosphatase/blood , Alveolar Bone Loss/physiopathology , Alveolar Process/drug effects , Alveolar Process/pathology , Animals , Anti-Inflammatory Agents/pharmacology , Bone Density/drug effects , Calcium/blood , Cell Count , Dinoprostone/analysis , Down-Regulation , Gingiva/drug effects , Gingiva/pathology , Interleukin-1beta/analysis , Male , Mouth Mucosa/drug effects , Mouth Mucosa/pathology , Nitric Oxide Synthase Type II/analysis , Osteoblasts/drug effects , Osteoblasts/pathology , Osteoclasts/drug effects , Osteoclasts/pathology , Phosphorus/blood , Random Allocation , Rats , Rats, Sprague-Dawley
13.
Periodontia ; 19(2): 86-92, 2009. ilus, tab
Article in Portuguese | LILACS, BBO - Dentistry | ID: lil-576691

ABSTRACT

Os metabólitos do ácido araquidônico exercem um reconhecido papel na patogênese da doença periodontal. O objetivo deste trabalho foi avaliar o efeito do celecoxib, um inibidor seletivo da enzima cicloxigenase-2 (COX-2), sobre o processo inflamatório durante o desenvolvimento de doença periodontal induzida por ligadura em ratos. Após a colocação de ligadura de algodão ao redor dos primeiros molares inferiores direitos, 108 ratos Wistar foram aleatoriamente subdivididos em três grupos experimentais com 36 animais cada. Nos grupos teste (Ce1 e Ce2), os animais receberam diariamente uma dose oral de celecoxib 10 mg ou 20 mg/ kg de peso corporal, respectivamente. No grupo controle, os animais receberam diariamente dose oral de 1ml/kg de peso corporal de cloreto de sódio (NaCl) a 0,9%. Aos 5, 18 e 30 dias após o início do experimento, 12 animais de cada grupo experimental foram sacrificados. As mandíbulas foram retiradas e submetidas à análise histológica. Observou-se através de análise estatística como teste não-paramétrico de Kruskal-Wallis, que o tratamento com celecoxib, em ambas as concentrações, diminuiu a magnitude do processo inflamatório agudo e, reduziu significativamente (p<0,05) a intensidade do infiltrado inflamatório crônico. Estes resultados demonstraram que, independentemente da dosagem utilizada, a inibição seletivada COX-2 através do celecoxib pode levar a um decréscimo da reação inflamatória do tecido periodontal em decorrência da presença de ligadura em ratos.


Arachidonic acid metabolites have a recognized role in the pathogenesis of periodontal disease. The purpose of this study was to evaluate the effect of a selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, on the progression of periodontal disease in a ligature-induced periodontitis model in rats. After ligature placement in the mandibular right first molars, 108, 6-week-old Wistar rats were ramdomly assigned to one of the following groups of treatment that consisted in a daily oral dose of 10mg/kg body weight of celecoxib (Ce1), 20mg/kg body weight of celecoxib (Ce2) or 10ml/kg of 0,9%NaCl (Control). At 5, 18 and 30 days later, 12 animals of each group were sacrificed and the specimens routinely processed. Treatment with celecoxib significantly (p < 0,05) decreased the acute and the chronic process, histologically observed. These results show that selective cyclooxygenase-2 (COX-2) inhibition with celecoxib, can decrease the periodontal inflammation due to ligature placement in rats.


Subject(s)
Animals , Rats , Alveolar Bone Loss , Anti-Inflammatory Agents, Non-Steroidal , Periodontal Diseases
14.
Histol Histopathol ; 23(10): 1177-84, 2008 10.
Article in English | MEDLINE | ID: mdl-18712669

ABSTRACT

Recent studies have suggested that tacrolimus monotherapy is a beneficial therapeutic alternative for the normalization of cyclosporin-induced bone loss in animal models and humans. The mechanism accounting for this action is unclear at present. In the present study, we attempted to determine the effect of tacrolimus monotherapy on alveolar bone using histological, histomorphometric and transmission electron microscopy (TEM). Groups of rats (n=10 each) were treated with either tacrolimus (1mg/kg/day, s.c.) or drug vehicle for 60 days. Fragments containing maxillary molars were processed for light microscopy to investigate the alveolar bone volume, trabecular separation, number of osteoclasts and osteoblasts, and transmission electron microscopy to investigate their ultrastructural basic phenotype. Treatment with tacrolimus monotherapy during 60 days may induce increases in alveolar bone volume (BV/TV,%; P<0.05) and a non-significant decrease in trabecular separation (Tb.Sp,mm; P>0.05), represented by a decrease in osteoclast number (N.Oc/BS; P<0.05) and maintenance of osteoblast number (N.Ob/BS; P>0.05). Osteoblasts were often observed as a continuous layer of active cells on the bone surface. Osteoclasts appeared to be detached from the resorbed bone surface, which was often filled by active osteoblasts and collagen-rich matrix. Moreover, osteoclasts in the treated group were frequently observed as inactive cells (without ruffled border, clear zone and detached from the bone surface). Within the limits of the present study, we conclude that tacrolimus leads to an increase in alveolar bone formation, which probably exerts action on osteoclasts. Tacrolimus could, therefore, play a crucial role in the control of both early osteoclast differentiations from precursors, as well as in functional activation.


Subject(s)
Alveolar Bone Loss/physiopathology , Immunosuppressive Agents/pharmacology , Maxilla/drug effects , Maxillary Diseases/physiopathology , Osteoclasts/drug effects , Osteogenesis/drug effects , Tacrolimus/pharmacology , Alveolar Bone Loss/pathology , Animals , Immunosuppressive Agents/administration & dosage , Injections, Subcutaneous , Male , Maxilla/physiopathology , Maxilla/ultrastructure , Maxillary Diseases/pathology , Microscopy, Electron, Transmission , Osteoblasts/drug effects , Osteoblasts/ultrastructure , Osteoclasts/ultrastructure , Rats , Rats, Sprague-Dawley , Tacrolimus/administration & dosage , Time Factors
15.
J Oral Rehabil ; 35(11): 836-46, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18466276

ABSTRACT

UNLABELLED: The effectiveness of microwave disinfection of maxillary complete dentures on the treatment of Candida-related denture stomatitis was evaluated. Patients (n = 60) were randomly assigned to one of four treatment groups of 15 subjects each; CONTROL GROUP: patients performed the routine denture care; Mw group: patients had their upper denture microwaved (650 W per 6 min) three times per week for 30 days; group MwMz: patients received the treatment of Mw group in conjunction with topical application of miconazole three times per day for 30 days; group Mz: patients received the antifungal therapy of group MwMz. Cytological smears and mycological cultures were taken from the dentures and the palates of all patients before treatment at day 15 and 30 of treatment and at follow-up (days 60 and 90). The effectiveness of the treatments was evaluated by Kruskal-Wallis and Mann-Whitney tests. Microbial and clinical analysis of the control group demonstrated no significant decrease in the candidal infection over the clinical trial. Smears and cultures of palates and dentures of the groups Mw and MwMz exhibited absence of Candida at day 15 and 30 of treatment. On day 60 and 90, few mycelial forms were observed on 11 denture smears (36.6%) from groups Mw and MwMz, but not on the palatal smears. Miconazole (group Mz) neither caused significant reduction of palatal inflammation nor eradicated Candida from the dentures and palates. Microwaving dentures was effective for the treatment of denture stomatitis. The recurrence of Candida on microwaved dentures at follow-up was dramatically reduced.


Subject(s)
Candidiasis, Oral/radiotherapy , Denture, Complete, Upper/microbiology , Disinfection/methods , Microwaves , Stomatitis, Denture/radiotherapy , Adult , Aged , Aged, 80 and over , Antifungal Agents/therapeutic use , Candida albicans/isolation & purification , Candidiasis, Oral/drug therapy , Dental Disinfectants/therapeutic use , Female , Humans , Male , Miconazole/therapeutic use , Middle Aged , Stomatitis, Denture/drug therapy , Stomatitis, Denture/microbiology
16.
Oral Dis ; 14(1): 67-72, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18173451

ABSTRACT

BACKGROUND: Tacrolimus, an immunosuppressive drug used in organ transplantation, has been reported not to induce gingival overgrowth. However, prevalence studies are limited, and the methods used for assessing gingival overgrowth varies among studies. OBJECTIVE: The purpose of this study was to evaluate the effects of up to 240 days of tacrolimus therapy on gingival tissues of rats. MATERIALS AND METHODS: Rats were treated for 60, 120, 180 and 240 days with daily subcutaneous injections of 1 mg/kg body weight of tacrolimus. After histological processing, the oral and connective tissue, volume densities of fibroblasts (Vf), collagen fibers (Vcf) and other structures (Vo) were assessed in the region of the lower first molar. RESULTS: After 60 and 120 days of treatment with tacrolimus, gingival overgrowth was not observed. The gingival epithelium, connective tissue, as well as the values for Vf, Vcf, and Vo were similar to those of the control rats (P>0.05). After 180 and 240 days of the treatment, gingival overgrowth was associated with a significant increase in the gingival epithelium and connective tissue as well as an increase in the Vf and Vcf (P<0.05). CONCLUSIONS: Within the limits of the experimental study, it may be concluded that the deleterious side effects of tacrolimus on the gingival tissues of rats may be time-related.


Subject(s)
Gingiva/drug effects , Immunosuppressive Agents/therapeutic use , Tacrolimus/therapeutic use , Animals , Cell Count , Collagen/drug effects , Connective Tissue/drug effects , Connective Tissue/pathology , Epithelium/drug effects , Epithelium/pathology , Fibroblasts/drug effects , Gingiva/pathology , Gingival Hyperplasia/chemically induced , Gingival Hyperplasia/pathology , Gingival Overgrowth/chemically induced , Gingival Overgrowth/pathology , Immunosuppressive Agents/administration & dosage , Injections, Subcutaneous , Male , Mouth Mucosa/drug effects , Mouth Mucosa/pathology , Random Allocation , Rats , Rats, Sprague-Dawley , Tacrolimus/administration & dosage , Time Factors
17.
J Periodontal Res ; 42(5): 466-73, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17760825

ABSTRACT

BACKGROUND AND OBJECTIVE: Cyclosporine A is an immunosuppressive drug that is widely used in organ transplant patients as well as to treat a number of autoimmune conditions. Bone loss is reported as a significant side-effect of cyclosporine A use because this can result in serious morbidity of the patients. As we have shown that cyclosporine A-associated bone loss can also affect the alveolar bone, the purpose of this study was to evaluate the effect of the concomitant administration of alendronate on alveolar bone loss in a rat model. MATERIAL AND METHODS: Forty Wistar rats (10 per group) were given cyclosporine A (10 mg/kg, daily), alendronate (0.3 mg/kg, weekly), or both cyclosporine A and alendronate, for 60 d. The control group received daily injections of sterile saline. The expression of proteins associated with bone turnover, including osteocalcin, alkaline phosphatase and tartrate-resistant acid phosphatase (TRAP), and also the calcium levels, were evaluated in the serum. Analysis of the bone volume, alveolar bone surface, the number of osteoblasts per bone surface and the number of osteoclasts per bone surface around the lower first molars was also performed. RESULTS: The results indicate that cyclosporine A treatment was associated with bone resorption, represented by a decrease in the bone volume, alveolar bone surface and the number of osteoblasts per bone surface and by an increase in the number of osteoclasts per bone surface and TRAP-5b. These effects were effectively counteracted by concomitant alendronate administration. CONCLUSION: It is concluded that concomitant administration of alendronate can prevent cyclosporine A-associated alveolar bone loss.


Subject(s)
Alendronate/therapeutic use , Alveolar Bone Loss/chemically induced , Bone Density Conservation Agents/therapeutic use , Cyclosporine/adverse effects , Immunosuppressive Agents/adverse effects , Acid Phosphatase/blood , Alendronate/administration & dosage , Alkaline Phosphatase/blood , Alveolar Bone Loss/pathology , Alveolar Bone Loss/prevention & control , Alveolar Process/drug effects , Alveolar Process/pathology , Animals , Biomarkers/blood , Bone Density/drug effects , Bone Density Conservation Agents/administration & dosage , Calcium/blood , Cell Count , Disease Models, Animal , Isoenzymes/blood , Male , Osteoblasts/drug effects , Osteoblasts/pathology , Osteocalcin/blood , Osteoclasts/drug effects , Osteoclasts/pathology , Random Allocation , Rats , Rats, Wistar , Tartrate-Resistant Acid Phosphatase
18.
Arch Oral Biol ; 52(9): 882-8, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17367747

ABSTRACT

OBJECTIVE: Periodontitis is a well-appreciated example of leukocyte-mediated bone loss and inflammation with pathogenic features similar to those observed in other inflammatory diseases, such as arthritis. Since Tacrolimus, is an immunomodulatory drug used for the treatment of some cases of arthritis, we hypothesized that it may modulate periodontal disease. DESIGN: Using a murine model of ligature-induced periodontal disease, we assessed the effects of daily administrations of Tacrolimus (1mg/kg body weight) on bone loss, enzymatic (myeloperoxidase) analysis, differential white blood cells counts, airpouch exudate and cytokine expression for 5-30 days. RESULTS: Radiographic, enzymatic (myeloperoxidase) and histological analysis revealed that Tacrolimus reduced the severity of periodontitis. More specifically, Tacrolimus suppressed the expression of serum interleukin (IL-1beta), tumour necrosis factor (TNF-alpha), IL-6, airpouch exudate PGE(2) and leukocytosis usually observed after the induction of periodontitis. Tacrolimus treatment in periodontitis-induced rats conferred protection against the inflammation-induced tissue and bone loss associated with periodontitis, through a mechanism involving IL-1beta, TNF-alpha and IL-6. CONCLUSIONS: The effects of Tacrolimus on periodontal disease pathogenesis may provide clues to a novel approach to host modulation therapy in destructive periodontal disease.


Subject(s)
Calcineurin Inhibitors , Immunosuppressive Agents/therapeutic use , Periodontitis/prevention & control , Tacrolimus/therapeutic use , Alveolar Bone Loss/prevention & control , Animals , Dinoprostone/analysis , Disease Models, Animal , Gingiva/drug effects , Gingiva/enzymology , Immunologic Factors/therapeutic use , Interleukin-1beta/blood , Interleukin-1beta/drug effects , Interleukin-6/blood , Leukocyte Count , Leukocytosis/prevention & control , Male , Periodontitis/enzymology , Peroxidase/analysis , Rats , Rats, Wistar , Time Factors , Tumor Necrosis Factor-alpha/analysis , Tumor Necrosis Factor-alpha/drug effects
19.
Oral Dis ; 12(3): 242-53, 2006 May.
Article in English | MEDLINE | ID: mdl-16700733

ABSTRACT

Opportunistic fungal pathogens are becoming increasingly important causes of both community-acquired and nosocomial infections. The most important fungal pathogens are yeast species belonging to the genus Candida. These species show differences in levels of resistance to antifungal agents and mortality. Consequently, it is important to correctly identify the causative organism to the species level. Identification of Candida dubliniensis in particular remains problematic because of the high degree of phenotypic similarity between this species and Candida albicans. However, as the differences between both are most pronounced at the genetic level, several studies have been conducted in order to provide a specific and rapid identification fingerprinting molecular test. In most candidal infectious, no single DNA fingerprinting technique has evolved as a dominant method, and each method has its advantages, disadvantages and limitations. Moreover, the current challenge of these techniques is to compile standardized patterns in a database for interlaboratory use and future reference. This review provides an overview of most common molecular fingerprinting techniques currently available for discrimination of C. albicans and C. dubliniensis.


Subject(s)
Candida albicans/genetics , Candida/classification , Candida/genetics , Candidiasis, Oral/microbiology , DNA Fingerprinting/methods , Mycological Typing Techniques , DNA, Fungal/analysis , Electrophoresis/methods , Electrophoresis, Polyacrylamide Gel/methods , Enzymes/chemistry , Genetic Variation , Humans , Karyotyping/methods , Microsatellite Repeats/genetics , Nucleic Acid Amplification Techniques , Polymorphism, Restriction Fragment Length , Random Amplified Polymorphic DNA Technique
20.
Oral Dis ; 12(3): 309-14, 2006 May.
Article in English | MEDLINE | ID: mdl-16700742

ABSTRACT

OBJECTIVE: The aim of this study was to determine the oral status of renal transplant recipients receiving cyclosporin A (CsA) or tacrolimus (FK-506) as immunosuppressant. SUBJECTS AND METHODS: A total of 88 renal transplant recipients receiving CsA (63 men and 25 women, mean age 51.4 years) and 67 receiving FK-506 (57 men and 10 women, mean age 33.5 years) were included in the study. Donor type, histocompatibility, cold ischemia time and prior delayed graft function were similar between the two groups. Demographics and pharmacological data were recorded for all subjects. RESULTS: The results demonstrated that CsA caused a greater number of oral diseases. A greater number of gingival overgrowth was present in patients treated with CsA. However, the combined use with calcium channel blockers increased the gingival overgrowth number. The occurrence of candida in saliva was observed in 80 renal recipients treated with CsA and 20 treated with FK-506. The presence of squamous oral carcinoma (n = 3) and herpes simplex (n = 10) was observed in patients treated with CsA. These alterations were not observed in renal recipients treated with FK-506. CONCLUSIONS: Renal recipients constitute a high-risk group for oral diseases, as they are immunocompromised. However, the FK-506 regime appears to ameliorate this effect, compared with CsA. Adequate pre- and post-transplant oral health care is recommended for these subjects, irrespective of the time interval for which the drug is administered.


Subject(s)
Cyclosporine/adverse effects , Gingival Overgrowth/chemically induced , Immunosuppressive Agents/adverse effects , Kidney Transplantation/adverse effects , Tacrolimus/adverse effects , Adult , Calcium Channel Blockers/adverse effects , Candida/isolation & purification , Carcinoma, Squamous Cell/etiology , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Mouth Neoplasms/etiology , Saliva/microbiology , Stomatitis, Herpetic/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...